Chronic Hepatitis

The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the company announced in a press release.

The FDA has granted fast track designation to GSK’s bepirovirsen, a triple action investigational antisense oligonucleotide, for the treatment of chronic hepatitis B virus infection, according to a manufacturer release.

Metabolic comorbidities heightened risk for adverse liver-related events among patients with chronic hepatitis B virus, with the highest risk found among patients with multiple comorbidities, according to research.

Although Black individuals with chronic hepatitis B were less likely to meet treatment criteria, researchers reported no significant differences in treatment initiation between racial groups, according to data in JAMA Network Open.

Being prescribed a 90-day or a “mixed duration” supply of entecavir or tenofovir disoproxil fumarate was associated with higher fill rates among commercially insured patients with chronic hepatitis B, researchers found.

WASHINGTON — Bulevirtide monotherapy was safe and effective at 72 weeks for patients with hepatitis D virus-related compensated cirrhosis, with virological and clinical responses increasing over time, according to data presented here.

LONDON — Bulevirtide induced a greater combined virologic and biochemical response compared with control at 48 weeks in patients with chronic hepatitis D infection, according to research.

Core protein allosteric modulator RO7049389 was safe and demonstrated antiviral activity in patients with chronic hepatitis B infection, according to research published in Lancet Gastroenterology and Hepatology.

Peer support within marginalized groups at risk for hepatitis C virus increased treatment initiation and completion as well as improved outcomes, according to a presenter at The International Liver Congress.

Intelligent liver function testing successfully identified patients with hepatitis C who were previously undiagnosed, many of whom did not fit traditional at-risk profiles, according to a presentation at the International Liver Conference.